Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age.

Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother (2013) 0.89

Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom. Clin Vaccine Immunol (2008) 0.85

Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation. Arch Dis Child (1996) 0.83

Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age. Can J Infect Dis Med Microbiol (2007) 0.81

Population-based surveillance of Hib invasive infections in children in British Columbia Alberta and Ontario - 1995 to 1997. Can J Infect Dis (2000) 0.81

Supplementary statement on newly licensed Haemophilus influenzae type B (Hib) conjugate vaccines in combination with other vaccines recommended for infants. CMAJ (1995) 0.78

Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol (1994) 2.43

Assessment of a universal, school-based hepatitis B vaccination program. JAMA (1995) 2.23

Local adverse effects of meningococcal vaccine. CMAJ (1994) 1.66

Increasing incidence of ampicillin resistance in Hemophilus influenzae. J Pediatr (1978) 1.63

Serious Pasteurella multocida infections from lion and tiger bites. JAMA (1985) 1.29

The Immunization Monitoring Program Active (IMPACT) prospective five year study of Canadian children hospitalized for chickenpox or an associated complication. Pediatr Infect Dis J (2000) 1.27

Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program--Active (IMPACT). Clin Infect Dis (1999) 1.26

Inactivated poliovirus vaccine: past and present experience. Vaccine (1996) 1.22

Evaluation of adverse events after influenza vaccination in hospital personnel. CMAJ (1990) 1.20

Historic low Haemophilus influenzae type B case tally--Canada 2000. Can Commun Dis Rep (2001) 1.17

Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel. CMAJ (1991) 1.16

Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus B conjugate vaccine administered to infants at two, four and six months of age. Vaccine (1998) 1.14

Meningococcal disease and vaccination in North America. J Paediatr Child Health (2001) 1.14

Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. J Pediatr (1997) 1.10

Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health (1998) 1.08

Invasive pneumococcal infections among Canadian aboriginal children. Can Commun Dis Rep (2003) 1.05

An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine (2000) 1.05

Adverse reactions to the preschool (fifth) dose of adsorbed diphtheria-pertussis-tetanus vaccine in Canadian children. CMAJ (1991) 1.04

Otitis media caused by non-typable, ampicillin-resistant strains of Haemophilus influenzae. J Pediatr (1976) 0.99

Disseminated bacille Calmette-Guérin infection: three recent Canadian cases. IMPACT. Immunization Monitoring Program, Active. Can Commun Dis Rep (1998) 0.97

Epidemic and endemic seroprevalence of antibodies to Cryptosporidium and Giardia in residents of three communities with different drinking water supplies. Am J Trop Med Hyg (1999) 0.97

Measles vaccination of infants in a well-vaccinated population. Pediatr Infect Dis J (1995) 0.97

Comparative safety of tetanus-diphtheria toxoids booster immunization in students in Grades 6 and 9. Pediatr Infect Dis J (1998) 0.97

Prevention and treatment of influenza A with amantadine hydrochloride. Can Med Assoc J (1980) 0.96

Population-based incidence rate of invasive pneumococcal infection in children: Vancouver, 1994-1998. Can Commun Dis Rep (2000) 0.94

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC): the politics and positives of a cooperative study group for the PICNIC. J Clin Epidemiol (1997) 0.93

Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine (2012) 0.93

Haemophilus influenzae type B disease at 11 pediatric centres, 1996-1997. Can Commun Dis Rep (1998) 0.90

An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics (1999) 0.90

A swimming pool-associated outbreak of Cryptosporidiosis in British Columbia. Can J Public Health (1994) 0.89

Giardiasis outbreak from a chlorinated community water supply. Can J Public Health (1991) 0.88

Effects of freezing on DPT and DPT-IPV vaccines, adsorbed. Can Commun Dis Rep (1995) 0.87

Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine (2007) 0.86

Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine (2008) 0.86

Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J (2000) 0.85

Failures after immunization with Haemophilus influenzae type b vaccines--1991-1995. Can Commun Dis Rep (1996) 0.84

Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? CMAJ (1993) 0.83

An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine (2006) 0.83

Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children. Vaccine (1995) 0.83

Immunogenicity of Haemophilus influenzae type b conjugate vaccine in children with congenital asplenia. J Infect Dis (1993) 0.82

Children hospitalized with influenza during the 2006-2007 season: a report from the Canadian Immunization Monitoring Program, Active (IMPACT). Can Commun Dis Rep (2008) 0.82

Epidemiology of meningococcal disease in north america. Methods Mol Med (2001) 0.82

Local adverse reactions to adsorbed DPT vaccine--Surrey, British Columbia. Can Dis Wkly Rep (1989) 0.82

Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria. Clin Exp Immunol (1991) 0.81

Controlled trial of Haemophilus influenzae type B diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month-old children, including comparison of arm versus thigh injection. Vaccine (1992) 0.81

Reactogenicity to a live attenuated varicella vaccine in Canadian children. Can J Infect Dis (2000) 0.81

Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine (1999) 0.81

Pertussis in children hospitalized at five Canadian pediatric tertiary care centres. Can Commun Dis Rep (1994) 0.80

Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J (1999) 0.80

Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia. Can Dis Wkly Rep (1989) 0.80

Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine (1996) 0.79

Incidence of ampicillin-resistant Hemophilus influenzae in otitis media. J Pediatr (1976) 0.79

Breastfeeding and antibody responses to routine vaccination in infants. Lancet (1992) 0.79

Streptococcal neonatal osteomyelitis. Am J Dis Child (1980) 0.79

Decline in Haemophilus influenzae type B invasive infections at five Canadian pediatric centres. Can Commun Dis Rep (1993) 0.78

Evaluation of skin antisepsis prior to blood culture in neonates. Infect Control (1984) 0.78

[Quality evaluation of primary health care in an urban area of southern Brazil]. Rev Saude Publica (1994) 0.78

Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old. Scand J Infect Dis (1995) 0.77

Immunogenicity of a five-component acellular pertussis vaccine in infants and young children. Arch Pediatr Adolesc Med (1994) 0.77

Measuring protection; a case study of pertussis vaccines--Swedish Trial II: secondary non-randomized comparisons between two schedules of infant vaccination. Dev Biol Stand (1998) 0.77

Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine. Vaccine (1997) 0.76

Extended follow-up of antibody levels and antigen responsiveness after 2 Haemophilus influenzae type b conjugate vaccines. J Pediatr (1999) 0.76

Controlled study of a new five-component acellular pertussis vaccine in adults and young children. J Infect Dis (1992) 0.76

Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. Arch Pediatr Adolesc Med (1994) 0.76